deltatrials
Completed PHASE3 INTERVENTIONAL 1-arm NCT01339559

Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy (BRITE™)

An Open-label, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older With Epilepsy

Sponsor: UCB BIOSCIENCES, Inc.

Conditions Epilepsy
Interventions Brivaracetam
Updated 20 times since 2017 Last updated: Aug 16, 2021 Started: May 11, 2011 Primary completion: Apr 18, 2019 Completion: Apr 18, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01339559, this PHASE3 trial focuses on Epilepsy and remains completed. Sponsored by UCB BIOSCIENCES, Inc., it has been updated 20 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Oct 2017 · 4 months · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Apr 2018 · 4 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Sep 2018 · 2 months · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Apr 2019 · 6 months · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2020 · 13 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jul 2024 · 34 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

20 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Sep 2021 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 15 earlier versions

  1. Jan 2021 — Sep 2021 [monthly]

    Completed PHASE3

  2. Jul 2020 — Jan 2021 [monthly]

    Completed PHASE3

  3. Jun 2019 — Jul 2020 [monthly]

    Completed PHASE3

  4. May 2019 — Jun 2019 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  5. Apr 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE3

  6. Oct 2018 — Apr 2019 [monthly]

    Active Not Recruiting PHASE3

  7. Sep 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Jul 2018 — Sep 2018 [monthly]

    Active Not Recruiting PHASE3

  9. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  10. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  11. Dec 2017 — Apr 2018 [monthly]

    Active Not Recruiting PHASE3

  12. Oct 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE3

  13. Jun 2017 — Oct 2017 [monthly]

    Active Not Recruiting PHASE3

  14. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE3

  15. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE3

    First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • UCB BIOSCIENCES, Inc.
Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aguascalientes, Mexico , Alytus, Lithuania , Ames, United States , Asheville, United States , Atlanta, United States , Aurora, United States , Austin, United States , Bangalore, India , Barcelona, Spain , Bari, Italy and 143 more locations